Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.
暂无分享,去创建一个
Jean-Claude Tardif | Eran Leitersdorf | Lawrence A Leiter | J. McMurray | B. Chaitman | J. Tardif | P. Shah | I. Holme | C. Ballantyne | A. Olsson | G. Schwartz | E. Leitersdorf | D. Kallend | Bernard R Chaitman | Christie M Ballantyne | John J V McMurray | Gregory G Schwartz | Anders G Olsson | Ingar M Holme | David Kallend | Prediman K Shah | Phillip J Barter | Regina Duttlinger-Maddux | John Mathieson | P. Barter | R. Duttlinger-Maddux | J. Mathieson | Regina Duttlinger-Maddux
[1] A. Tall,et al. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[2] M. Ezekowitz,et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. , 2005, European heart journal.
[3] George Steiner,et al. Safety and tolerability of dalcetrapib. , 2009, The American journal of cardiology.
[4] F. Zimetti,et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits Published, JLR Papers in Press, February 26, 2007. , 2007, Journal of Lipid Research.
[5] S. Yusuf,et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.
[6] K. Wakitani,et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits , 2000, Nature.
[7] C. Shear,et al. Inhibition of Cholesteryl Ester Transfer Protein by Torcetrapib Modestly Increases Macrophage Cholesterol Efflux to HDL , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[8] E. Stroes,et al. Dalcetrapib: no off‐target toxicity on blood pressure or on genes related to the renin‐angiotensin‐aldosterone system in rats , 2009, British journal of pharmacology.
[9] Michael F. Oliver,et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.
[10] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[11] Colin Berry,et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. , 2007, JAMA.
[12] Jean-Claude Tardif,et al. Effect of torcetrapib on the progression of coronary atherosclerosis. , 2007, The New England journal of medicine.
[13] M. Pfeffer,et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. , 2006, Circulation.
[14] D. Grobbee,et al. Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia , 2007 .
[15] C. Maugeais,et al. Inhibition of cholesteryl ester transfer protein (CETP): Different in vitro characteristics of RO4607381/JTT-705 and torcetrapib (TOR) , 2008 .
[16] P. Fitzgerald,et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. , 2010, Journal of the American College of Cardiology.
[17] D. Mozaffarian,et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.
[18] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[19] E. Tuzcu,et al. Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis: Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) , 2008, Circulation.
[20] G. Assmann,et al. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. , 1992, The American journal of cardiology.
[21] D. Mozaffarian,et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.
[22] P. Shah. Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease. , 2006, European heart journal.
[23] Paul Schoenhagen,et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.
[24] A. Tall,et al. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. , 2006, The Journal of clinical investigation.
[25] M. Caulfield,et al. Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.
[26] J. Danesh,et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. , 2008, JAMA.
[27] K. Marotti,et al. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein , 1993, Nature.
[28] H. Brewer,et al. Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. , 2006, The American journal of cardiology.
[29] M. Pfeffer,et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. , 2006, Journal of the American College of Cardiology.
[30] M. Sabatine,et al. Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. , 2008, JAMA.
[31] Christopher P Cannon,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[32] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[33] M C Hjortland,et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.
[34] A. Zwinderman,et al. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. , 2008, European heart journal.
[35] Jean-Claude Tardif,et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.
[36] A. Gotto,et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. , 2007, The New England journal of medicine.
[37] D. Rader,et al. Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[38] Adrian Hernandez,et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. , 2009, American heart journal.